Vaccination with live-attenuated polio vaccine has been the primary reason for the drastic reduction of poliomyelitis worldwide. However, reversion of this attenuated poliovirus vaccine occasionally results in the emergence of vaccine-derived polioviruses that may cause poliomyelitis. Thus, the development of anti-poliovirus agents remains a priority for control and eradication of the disease. MicroRNAs (miRNAs) have been shown to regulate viral infection through targeting the viral genome or reducing host factors required for virus replication. However, the roles of miRNAs in poliovirus (PV) replication have not been fully elucidated. In this study, a library of 1200 miRNA mimics was used to identify miRNAs that govern PV replication. High-throughput screening revealed 29 miRNAs with antiviral properties against Sabin-2, which is one of the oral polio vaccine strains. In particular, miR-555 was found to have the most potent antiviral activity against three different oral polio attenuated vaccine strains tested. The results show that miR-555 reduced the level of heterogeneous nuclear ribonucleoprotein C1/C2 (hnRNP C) required for PV replication in the infected cells, which in turn resulted in reduction of PV positive-strand RNA synthesis and production of infectious progeny. These findings provide the first evidence for the role of miR-555 in PV replication and reveal that miR-555 could contribute to the development of antiviral therapeutic strategies against PV.
INTRODUCTION
Poliovirus (PV) belongs to family Picornaviridae and is a non-enveloped single positive-strand RNA virus, which can cause poliomyelitis (Kitamura et al., 1981) . PV enters the host cell by binding to an immunoglobulin-like receptor, CD155 (He et al., 2003) , altering cellular processes so as to usurp host gene products to facilitate replication in the cytoplasm (Belov & Ehrenfeld, 2007; Nagy & Pogany, 2012) . Large-scale vaccination campaigns using oral polio vaccine made available through the Global Polio Eradication Initiative have been successful in reducing the incidence of poliomyelitis. However, the use of a liveattenuated vaccine has inadvertently created an increased risk of the emergence of vaccine-derived PVs (VDPVs) through natural reversion to WT virus, including the emergence of immune-deficiency-associated PV (iVDPV) and circulating vaccine-derived PV (cVDPV) which has the potential to cause clinical disease, including poliomyelitis (Guo et al., 2015; Minor, 2009 ). In addition, immunedeficient individuals can shed virus for years after vaccination, which has resulted in the risk of vaccine-derived paralytic poliomyelitis itself as well as potential reservoirs (Collett et al., 2008) . Consequently, the National Research Council of the (US) National Academies has suggested that the development of one or more antiviral compounds will be necessary to eradicate PV, and to prevent unexpected outbreaks of PVs at the post-eradication phase (McKinlay et al., 2014) . For this reason, many efforts are in place to develop efficacious anti-PV agents.
MicroRNAs (miRNAs) are small non-coding RNAs regulating target gene expression at the post-transcriptional level by binding to target mRNAs (Bartel, 2004; Filipowicz et al., 2008) . miRNAs have been known to be involved in a variety of cellular processes (Kedde & Agami, 2008; O'Connell et al., 2010) . Increasing evidence suggests that miRNAs have a critical role in the host-virus interaction during infection (Skalsky & Cullen, 2010; Umbach & Cullen, 2009; Wang et al., 2014) . Virus infection results in expression of viral proteins known to alter cellular miRNA expression to enhance virus replication (Farberov et al., 2015; Jopling et al., 2005) . However, miRNAs expressed by the infected host cell can act as a countermeasure to suppress virus replication through directly targeting viral RNA (Müller & Imler, 2007; Trobaugh2015; Hu et al., 2012; Huang et al., 2015) . Based on the accumulated findings, many efforts have focused on the development of miRNA-based therapeutics (Ruiz & Russell, 2015) . It is notable that the safety of MRX34, a liposomebased miR-34 mimic, has been tested in a clinical setting (Bouchie, 2013) , showing that there is a path forward for the potential use of miRNAs as a therapeutic agent in humans. However, the mechanism of how the miRNAs are involved in PV replication remains under-investigated.
In this study, the role of miRNAs in regulating PV vaccine strain replication was examined. To this end, a library of 1200 miRNA mimics was examined to identify miRNAs that inhibit PV replication. The study identified miR-555 as having robust antiviral properties against three oral polio vaccine strains. The antiviral effect of miR-555 was associated with a reduction of heterogeneous nuclear ribonucleoprotein C1/C2 (hnRNP C), which is a host factor critical for PV replication in the cytoplasm of HEp-2c cells during PV infection (Brunner et al., 2005; Ertel et al., 2010) . To our knowledge, this is the first study that has addressed the role of miR-555 in PV replication using high-throughput screening, and the findings provide insights into the first steps towards the development of miRNA-based antiviral agents against PV.
RESULTS

Identification of host miRNAs that govern PV infection
To identify miRNAs that govern PV replication, the library of 1200 miRNA mimics was screened in HEp-2c cells, which support PV replication (Fig. 1a) . Non-targeting miRNA mimic controls and the siRNA against PV were used as negative and positive controls, respectively, and included in each plate. HEp-2c cells were reverse-transfected with individual miRNA HEp-2c cells were reverse-transfected with a library of 1200 miRNA mimics at a final concentration of 20 nM. Non-targeting miRNA mimic controls (NTC) and siRNAs (siPolio) to PV were used as negative and positive controls, respectively. After 48 h, the cells were infected with Sabin-2 at an m.o.i. of 0.01 for 24 h and the effects of miRNAs were evaluated by ELISA. (b) Z-scores were calculated based on the results from the primary screen and were plotted according to rank, from miRNA with the lowest to that with the highest value. (c) The top 29 hits with antiviral activity from the primary screen were redetermined by ELISA as described in (a) and normalized to cells transfected with NTC. Asterisks mean 3p.
mimics, and after 48 h the cells were infected with PV Sabin-2 strain at an m.o.i. of 0.01 for 24 h. The effect of miRNAs on virus infection was analysed by ELISA and the results were normalized to the non-targeting miRNA mimic control (NTC). Z-scores were calculated based on the ELISA results and ranked from highest to lowest (Fig. 1b, Table 1 ). miRNAs with a Z-score jSD 21.5 causing cytotoxicity to cells were excluded from further studies. To confirm the antiviral effect of the 29 miRNAs discovered by the primary screening, the miRNAs were re-evaluated in triplicate in a separate assay using HEp-2c cells, followed by infection with Sabin-2 as in the primary screen. The results revealed that the 29 miRNAs had antiviral activity against Sabin-2 infection (Fig. 1c) , which was consistent with the findings observed in the primary screening.
Validation of miRNAs against Sabin-2
To validate the antiviral effect of miRNAs on the PV, the six top antiviral hits that had the highest level of inhibition were selected. These six top hits were re-examined to determine if they induced cytotoxicity in the HEp-2c cells. Cell viability assays revealed that transfecting the miRNAs did not cause cytotoxicity (Fig. 2a) , as cell viability was w85 %. The transfected cells were infected with Sabin-2, and the effect of miRNAs on the production of viral progeny was determined by plaque assay (Burns et al., 2006) . Transfection of several miRNAs resulted in a significant (Pv0.001) decrease in the number of viral plaques compared with mock-or mimic control (M-ctl)-transfected cells (Fig. 2b, c) . Of note, miR-555 mimic (M-555) exhibited the most potent antiviral activity. In contrast, transfection with miRNA inhibitors showed no significant effect on PV replication (data not shown), indicating that the endogenous level of miR-555 expressed in HEp-2c cells is negligible. Taken together, these results indicate that these six miRNAs are able to inhibit Sabin-2 replication without harming host cells.
Antiviral effects of miRNAs against different PV strains
To evaluate whether the selected miRNAs could inhibit replication of other PV vaccine strains, individual miRNA-transfected HEp-2c cells were infected (m.o.i. 0.01) with Sabin-1 or Sabin-3 strains, and the antiviral effect of miRNAs was determined by plaque assay. As shown in Fig. 3(a) , transfection with five miRNAs resulted in significant (Pv0.001) reduction of the number of Sabin-1 plaques compared with mock-or M-ctl-transfected HEp-2c cells, but miR-421 showed no detectable antiviral effect against Sabin-1. Considering the antiviral effect of these miRNAs against Sabin-3, four miRNAs -M-3118, M-134-5p, M-138-5p and M-555 -showed antiviral effect against Sabin-3 replication, while M-421 and M-424-3p did not influence PV replication (Fig. 3b) . These findings showed that M-3118, M-134-5p, M-138-5p and M-555 had antiviral effects against all three oral polio vaccine strains tested. Of these miRNAs, miR-555 showed the most potent antiviral activity, and thus we focused on understanding the function of miR-555 in PV replication for the remainder of the study.
hnRNP C expression is regulated by miR-555
Previous studies have shown that miRNAs can inhibit virus replication by targeting either the viral genome or host genes that support virus replication (Huang et al., 2015; Zheng et al., 2013) . To address how miR-555 might inhibit PV replication, the ViTa database was exploited to examine likely miRNA targets (Hsu et al., 2007) ; however, miR-555 regulates poliovirus replication no putative binding site for miR-555 was found in the PV genomes. To investigate if miR-555 inhibits PV by targeting endogenous genes involved in PV replication, the target genes of miR-555 were predicted by using the TargetScanHuman 6.2 prediction program (Grimson et al., 2007) and Ingenuity Pathway Analysis (IPA). The results revealed that 454 genes were predicted as targets of miR-555 via miRNA target filter analysis and that 52 out of 454 genes were associated with viral infection and replication ( Fig. 4a) . Of those genes, the hnRNP C gene, which has been shown to bind to PV protein 3CD and to the viral genome, a feature supporting PV positive-strand RNA synthesis, was revealed (Brunner et al., 2005; Ertel et al., 2010) . To evaluate if miR-555 targeted hnRNP C, HEp-2c cells were reverse-transfected with miR-555 mimic and the delivery of miR-555 mimic was confirmed by quantitative reverse transcription PCR (qRT-PCR) (Fig. 4b ). hnRNP C expression was determined at the mRNA and protein levels by qRT-PCR and Western blot, respectively, 48 h after transfection. The results showed that overexpression of miR-555 mimic in HEp-2c cells led to reduction of hnRNP C mRNA levels compared with mock-or M-ctl-transfected cells (Fig. 4c) . Furthermore, miR-555 mimic transfection showed a reduced hnRNP C protein level compared with mock-or M-ctl-transfected cells; however, miR-138, which also demonstrated anti-PV activity, showed no effect on hnRNP C protein expression (Fig. 4d) . To verify whether hnRNP C is a direct target of miR-555, a luciferase reporter plasmid containing the 39UTR of hnRNP C was constructed and a luciferase reporter assay was performed.
The results showed that transfection of miR-555 reduced the relative luciferase expression from the plasmid containing the 39UTR of hnRNP C as compared with mimic control, but not that from the plasmid without the 39UTR of hnRNP C (Fig. 4e) . These results indicate that miR-555 specifically regulates hnRNP C expression at the mRNA and protein levels in HEp-2 cells. Silencing of hnRNP C reduces PV replication in HEp-2c cells Although hnRNP C had been shown to be involved in PV replication (Brunner et al., 2005 Ertel et al., 2010) , it was important to confirm whether hnRNP C is important to PV replication in our system. Accordingly, HEp-2c cells were reverse-transfected with hnRNP C-specific small interfering (si) RNA (sihnRNP C) at 100 nM, and a reduction of hnRNP C mRNA levels was evident in HEp-2c cells compared with the control-treated groups (Fig. 5a ). The transfected cells were infected with Sabin-2 strain (m.o.i. 0.01) and the effect of the sihnRNP C on PV replication was evaluated by plaque assay. As shown in Fig. 5(b) , treatment with sihnRNP C significantly (Pv0.01) reduced the number of Sabin-2 plaques compared with control-transfected cells, consistent with the findings of a previous study, which reported that hnRNP C is involved in positive-strand RNA synthesis . Thus, we evaluated whether silencing of hnRNP C reduces PV positivestrand RNA synthesis at different time points post-infection at an m.o.i. of 1. The results showed that transfection of sihnRNP C resulted in a decreased level of PV positivestrand RNA at 4 h post-infection, and silencing of hnRNP C significantly (Pv0.01) reduced the positive-strand RNA levels at 8 and 12 h post-infection compared with siNTC ( Fig. 5c ). However, transfection of sihnRNP C did not affect PV positive-strand RNA level at 2 h post-infection, indicating that hnRNP C is not associated with the initial entry step. These results indicate that hnRNP C is vital for PV replication in HEp-2c cells.
Effect of miR-555 on PV positive-strand RNA synthesis
In this study it was shown that expression of miR-555 mimic inhibited hnRNP C at the mRNA and protein levels in HEp2c cells (Fig. 4) . To evaluate whether miR-555 inhibits PV positive-strand RNA synthesis by repressing hnRNP C, miR-555-transfected cells were infected (m.o.i. 1) with Sabin-2 and total RNA was extracted at 2, 4, 8 and 12 h post-infection. The levels of PV positive-strand RNA were determined by qRT-PCR. Similar to sihnRNP C, the transfection of miR-555 did not influence the level of PV positive-strand RNA at 2 h post-infection; however, miR-555 significantly (Pv0.001) reduced the level of PV positivestrand RNA at 8 and 12 h post-infection (Fig. 6) , which is consistent with the finding that silencing of hnRNP C reduced the levels of PV positive-strand RNA.
miR-555 reduces hnRNP C protein levels in the cytoplasm and nucleus of host cells infected with PV hnRNP C is relocalized to the cytoplasm during PV infection and has a role in stabilization of the PV genome and in PV positive-strand RNA synthesis (Gustin & Sarnow, 2001 ). Thus, it was important to evaluate if miR-555 inhibited PV replication by reducing hnRNP C in the cytoplasm during PV infection. miR-555-transfected HEp-2c cells were infected with Sabin-2 at an m.o.i. of 1 for 6 h, and the levels of hnRNP C protein in the cytoplasm and nucleus were assessed by Western blot. PV infection resulted in increased levels of hnRNP C protein in the cytoplasm compared with uninfected cells, while miR-555 markedly reduced the level of hnRNP C protein in the cytoplasm and nucleus compared with the M-ctl-treated cells under mock and PV infection (Fig. 7) . These results indicate that miR-555 inhibits PV positive-strand RNA synthesis in part by reducing the hnRNP C protein level in HEp-2c cells.
DISCUSSION
Despite eradication efforts, the risk of the emergence of cVDPV and iVDPV remains, as well as the risk of Error bars represent SEM, and the significant differences are compared with mock. *P,0.05, **P,0.01, ***P,0.001. M, mimic.
accidental exposure; thus there is a need for antiviral agents against PV (Guo et al., 2015; Minor, 2009) . miRNAs have been shown to have a critical role in governing host-virus interaction (Skalsky & Cullen, 2010; Umbach & Cullen, 2009 ); unfortunately, the involvement of miRNAs in regulating PV replication is poorly understood. In this study, the role of miR-555 as an antiviral PV agent was revealed;
it was shown that miR-555 possesses highly potent antiviral activity against all three oral polio vaccine strains, for which reversion to WT is of major concern (Minor, 2009 ). In addition, a mechanism of action was revealed, showing that miR-555 inhibits PV replication in part by reducing host factor hnRNP C in HEp-2c cells infected with PV. High-throughput screening revealed that at least 29 miRNAs were able to inhibit Sabin-2 replication. During the course of this study, other groups reported that PV transcript and protein levels were appreciably lower in ectopic miR-7 expressed in infected A549 cells (Zhang et al., 2015) . However, miR-7 was not included in the 29 miRNAs found from our screening data to have antiviral activity. This may be because miRNAs are expressed in tissue-specific expression patterns (Xu et al., 2007) , or expressed in response to different viruses. miRNAs have been shown to regulate virus infection either by directly targeting viral genome (Trobaugh et al., 2014; Zheng et al., 2013) or by governing host genes required for the virus life cycle (Fu et al., 2015; Huang et al., 2015) . A role for miR-555 directly targeting the PV genome was examined, but no putative binding site of miR-555 was revealed when three different Sabin strains (Sabin-1, Sabin-2, and Sabin-3) and their genome sequences were examined. However, it was predicted that miR-134-5p (with antiviral activity against the three Sabin strains in this study) had a putative binding site on three PV Sabin genome sequences, and miR-138-5p had a putative target site on the Sabin-3 genome. It is conceivable that these miRNAs may inhibit PV replication by targeting the PV genome, which is the subject of a different study.
hnRNP C is an abundant RNA-binding protein localized in the nucleus and exists in two isoforms resulting from alternative splicing (Dreyfuss et al., 1993; Görlach et al., 1992) . hnRNP C has a role in cellular mRNA biogenesis processes in the nucleus, including stability and host protein translation (Dreyfuss et al., 1993; Han et al., 2010) . Previous studies showed that hnRNP C was translocalized to the cytoplasm during PV infection (Gustin & Sarnow, 2001 ) and recruited to PV negative-strand RNA, which in turn supports PV positive-strand RNA synthesis . These findings are consistent with the observation in this study that silencing of hnRNP C reduced the level of PV positive-strand RNA in the cells following Sabin-2 infection. Apart from PV, hnRNP C is also involved in replication of other positivestrand RNA viruses, such as hepatitis C virus and dengue virus (Dechtawewat et al., 2015; Gontarek et al., 1999) . hnRNP C has been shown to interact with the 39 untranslated region (39UTR) of the hepatitis C virus and the transfection of sihnRNP C reduced the levels of dengue virus RNA and proteins. In consideration of these findings, it is possible that miR-555 may affect the replication of these viruses as miR-555 regulates poliovirus replication miR-555 significantly reduced hnRNP C at the mRNA and protein levels. miR-555 dramatically reduced PV mRNA level and viral yield, while silencing of hnRNP C exhibited less reduction in PV mRNA and yield compared with miR-555. It is possible that miR-555 may regulate other host genes required for PV replication, which is supported by the evidence that one miRNA can regulate large numbers of target mRNAs (Lim et al., 2005) . In this study, IPA analysis showed 52 target genes of miR-555 that are associated with viral infection. In addition, a previous study reported 65 positive and 155 negative regulators of PV infection (Sabin-2) using RNA interference screening (Coyne et al., 2011) . Of those genes whose depletion downregulated infection of PV, several, including DCKN2D, EPHA3, NAGS, TPM4 and USP4, were predicted to be target genes of miR-555 by IPA. It is conceivable that miR-555 may regulate PV infection by targeting the genes as well as hnRNP C, which will be further studied.
In conclusion, this study suggests that miR-555 could inhibit PV replication at least partially by targeting cellular hnRNP C in HEp-2c cells, and this finding could contribute to the development of miRNA-based antiviral therapy strategies against PV infection.
METHODS
Cell culture and viruses. HEp-2c cells were cultured in DMEM medium (Hyclone) supplemented with 10 % heat-inactivated FBS (Hyclone) and maintained in a 37 uC incubator with 5 % CO 2 . Oral polio vaccine Sabin strains were kindly provided by Dr Steve Oberste (CDC, Atlanta, GA). Stock viral titres were determined by plaque assay and 50 % cell culture infectious dose (CCID 50 ) (Arita et al., 2008) .
Screening and transfection of miRNA mimics. The miRNA mimic screen was performed in HEp-2c cells as shown in Fig. 1(a) .
The library of 1200 miRNA mimics (Dharmacon-Thermo Scientific) was reverse-transfected into HEp-2c cells at a final concentration of 20 nM in 0.4 % DharmaFect4 transfection reagent. Non-targeting miRNA mimics (Dharmacon) were used in all assays as negative controls, and siRNA (siPol) targeting the PV capsid-encoding region was utilized as positive control. Briefly, using a 96-well format, miRNA mimics were mixed with DharmaFect4 reagent in serum-free medium (OPTIMEM; Invitrogen) and incubated at room temperature for 20 min. HEp-2c cells were then added at 8000 cells per well in DMEM supplemented with 10 % FBS using Liqudator96 (Mettler Toledo). The cells were subsequently cultured in a 37 uC incubator with 5 % CO 2 . Forty-eight hours after transfection, the cells were infected with the oral polio vaccine strain Sabin-2 (m.o.i. 0.01) in 150 ml DMEM supplemented with 2 % FBS. At 24 h post-infection, the plates were sealed and frozen at 280 uC and stored until analysis by ELISA.
PV2 ELISA. The effect of miRNAs on Sabin-2 virus replication in HEp-2c cells was determined by employing a PV type 2-specific ELISA as previously described (Ivanov & Dragunsky, 2005) . Fifty microlitres of cell lysate was added to Immulon 2HB high-binding 96-well plates (Thermo Fisher) pre-coated with a PV type 2-specific monoclonal antibody (HYB294-06, mouse; Thermo Scientific Pierce). The plates were then incubated at 37 uC for 1 h. Subsequently, the plates were washed extensively with 1| PBS, followed by incubation with HRP-substrate solution (SureBlue TMB) for 15 min. The reaction was stopped by adding H 2 SO 4 stop solution. The plates were examined at a wavelength of 450 nm using a plate spectrophotometer (Tecan). The absorbance values were normalized to the controls, and converted to a Z-score for finalizing positive hits according to methods described previously (Bakre et al., 2013) . In this study, all hits with a Z-score jSD 21.5 were subject to further validation in HEp-2c cells.
Validation of miRNA hits. Individual miRNA mimics and inhibitors (Dharmacon) identified from the primary screen were reverse-transfected into HEp-2c cells at a final concentration of 20 nM as described above. At 48 h post-transfection, cells were infected with Sabin-1, -2 or -3 strains at an m.o.i. of 0.01. Cells were then incubated in a 37 uC incubator with 5 % CO 2 for 24 h, and frozen at 280 uC until analysis using plaque assay and CCID 50 (Arita et al., 2008) . Fig. 7 . miR-555 governs hnRNP C protein level in the cytoplasm of HEp-2c cells. HEp-2c cells were transfected with mock, M-ctl, and miR-555 mimic for 48 h, and the cells were infected with mock or the Sabin-2 strain at an m.o.i. of 1 for 6 h. The cytosolic and nuclear fractions were isolated and the hnRNP C protein levels were determined by Western blot. GAPDH and lamin B1 were used as internal controls.
Cytotoxicity assays. HEp-2c cells were reverse-transfected with individual miRNAs as described above. At 48 h post-transfection, cell viability was determined by CytoTox-Glo cytotoxicity assay (Promega) in accordance with the manufacturer's instructions. The results were normalized to siTOX control, which was considered 100 % cytotoxic.
Plaque assays. The virus titres were determined on HEp-2c cells by plaque assay (Burns et al., 2006) . Briefly, the cells were dispensed at 1.2|10 6 cells per well in six-well plates. Next day, the plates were washed with minimal essential medium (MEM; Hyclone, GE Healthcare, USA) containing 2 % FBS and incubated with the 10-fold serially diluted samples in a 37 uC incubator with 5 % CO 2 for 1 h. The medium was removed and the plates were overlaid with nutrient agarose gel (0.9 % agarose and 2| MEM supplemented with 4 % FBS at a ratio of 1 : 1), followed by incubation in a 37 uC incubator with 5 % CO 2 for 3 days. The cells were fixed with 10 % formaldehyde in PBS and the plaques were visualized by staining with crystal violet.
RNA extraction and qRT-PCR. Total RNA was extracted using RNAzol RT reagent (Molecular Research Center) according to the manufacturer's instruction. The concentration of total RNA was determined using a NanoDrop spectrophotometer (Thermo Scientific). To examine mature miR-555 expression, 500 ng total RNA was reverse-transcribed to cDNA using the miRNA 1st-Strand cDNA Synthesis kit (Agilent Technologies) according to the manufacturer's protocol. For the hnRNP C and PV gene, 300 ng total RNA was reverse-transcribed to cDNA using the AffinityScript QPCR cDNA synthesis kit (Agilent Technologies). Oligo(dT) primer was used for cDNA synthesis. For the quantification of individual genes, cDNAs were diluted in water and quantified using Brilliant III Ultra-Fast SYBR Green QPCR Master Mix (Agilent Technologies) in an Agilent Mx3005P instrument. Primers for miR-555 (forward, 59-CCGTAA-GCTGAACCTCTGATAA-39; reverse, universal primer), hnRNP C (forward, 59-TGGGCTGCTCTGTTCATAAG-39; reverse, 59-GCTC-TGCAGCCAGGTTAATA-39) and Sabin-2 (forward, 59-GTCACTC CACCCATAGACATAC-39; reverse, 59-GTCGCTCAACTCGACTCT-ATAC-39) were used. The gene expression levels were normalized to 18S rRNA gene as an internal control.
Western blot. The whole-cell lysates were harvested using RIPA buffer (1 % sodium deoxycholate, 1 % NP-40, 150 nM NaCl, 50 mM Tris/HCl, pH 7.2, 10 mM EDTA, 50 mM sodium fluoride), and the cytoplasmic and nuclear samples were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Reagent kit (Thermo Scientific) in accordance with the manufacturer's instructions. The protein concentration was measured by BCA Protein Assay kit (Thermo Scientific). Equivalent protein amounts were separated on a 4-20 % Tris/HCl precast SDS-PAGE gel (Bio-Rad) and transferred onto a PVDF membrane by using a submerged Trans-Blot apparatus (Bio-Rad). The membranes were blocked with TBS containing 5 % skimmed milk and incubated with mouse anti-hnRNP C (Abcam). After washing with TBST (TBS containing 0.1 % Tween-20), the membrane was probed with goat anti-mouse IgG conjugated to HRP (Millipore) and the band was visualized following reaction with chromogenic substrate (ECL kit; Thermo Scientific).
Luciferase reporter assay. Luciferase assay was performed as previously described (Bakre et al., 2012) . Briefly, The 39UTR of hnRNP C, containing a putative binding site for miR-555, was PCR-amplified from the genomic DNA of HEp-2c cells using primers specific for the 39UTR of hnRNP C (forward, 59-AAGCTTGCGGCCGCGCACATAGTGGGGT-TTAG-39; reverse, 59-CGAATTGCGGCCGCGACATGCCAACTCT-CATT-39) and cloned into the Not I site of the pMetluc control plasmid (Clontech) to generate gene-specific luc-UTR reporter plasmid, which was confirmed by DNA sequencing. HEp-2c cells were transfected with 200 ng gene-specific luc-UTR reporter plasmid, 20 ng pSEAP2 control plasmid (Clontech) and 20 nM miR-555 mimic or mimic control using Lipofectamine 2000 (Invitrogen). The luciferase activity was measured 48 h post-transfection using the Dual Secreted Reporter Assay kit (Clontech) according to manufacturer's instructions.
siRNA transfection. The siRNA (SMART pool: ON-TARGET plus hnRNP C) against the hnRNP C gene was purchased from Dhamacon. The siRNA was reverse-transfected into HEp-2c cells at a final concentration of 100 nM, as described in 'Screening and transfection of miRNA mimics' above.
Statistical analysis. All results were presented as means+SE. The statistical analyses were done using one-way ANOVA with Tukey's multiple comparison at 95 % confidence level in GraphPad Prism5 analysis software. P-values v0.05 were considered significant.
